Antheia Appoints John Nicols to Chair its Board of Directors
Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors. Nicols joins co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang on the Antheia Board of Directors.
Antheia’s 2022 in Review: A Year of Value
This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Antheia Announces New Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
Syn Bio Companies Put the Earth into Focus
While some synthetic biology companies are using biology to improve our food, clothes, and medicine, others are turning their attention to helping the Earth.
Biomanufacturing draws hundreds of millions in investments
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…
Antheia Raises $73M in Series B
Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire…
Antheia Secures $73M in Series B
Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B funding…
Antheia raises $73 million for drugs from reprogrammed yeast
Antheia, a synthetic biology company cofounded and led by Stanford University bioengineer Christina Smolke, has raised $73 million in series B financing…
The Funded: Accel and three unicorns score jumbo deals at midweek
Antheia Inc., Menlo Park, $73 million: Viking Global Investors led the Series B funding of this company that’s making plant-based medicines using synthetic biology. Sherpalo Ventures and Eric Schmidt’s Hillspire…
Money on the Move: June 30 – July 6
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary active…